Martina B, Staub J J, Gemsenjäger E
Medizinische Universitäts-Poliklinik, Departement für Innere Medizin, Kantonsspital Basel.
Schweiz Med Wochenschr. 1992 Nov 14;122(46):1753-7.
We analyzed the postoperative longterm results after strumectomy for sporadic goiter in 26 patients. The follow-up time was 25.1 +/- 14.7 (7-58) years (x +/- SD, extremes). Actual goiter recurrence without need for surgery was observed and sonographically confirmed in 3 patients, and 1 patient without actual recurrence had had a second strumectomy for goiter recurrence in the past. Hence the overall frequency of goiter recurrence in this study is 15% (4/26 patients). The patients with a present recurrence (n = 3) were significantly younger at the time of operation (29 +/- 11, 14-41 years) than those without recurrence (n = 23; 45 +/- 11, 28-60 years; p < 0.001). No patient had clinical endocrine dysfunction. Only four patients had been treated with thyroxine and they all suppressed TSH in the presence of euthyroid FT4 and T3 levels without present recurrence of goiter. 22 patients had no thyroid hormone prophylaxis and in only four of them (18%) was observed a recurrence in the longterm follow-up without endemic iodine deficiency. Prophylaxis with thyroid hormones often is not required in low risk patients operated upon and carefully controlled after strumectomy from non-iodine-deficient regions. Patients at risk for recurrence (second strumectomy, family history, elevated TSH, clinical or sonographic evidence for thyroid growth) should be considered for thyroxine therapy with regular follow-up.
我们分析了26例散发性甲状腺肿患者行甲状腺切除术后的长期结果。随访时间为25.1±14.7(7 - 58)年(x±标准差,范围)。观察到3例患者出现无需手术的实际甲状腺肿复发,并经超声证实,1例无实际复发的患者过去曾因甲状腺肿复发接受二次甲状腺切除术。因此,本研究中甲状腺肿复发的总体发生率为15%(4/26例患者)。目前复发的患者(n = 3)手术时的年龄(29±11,14 - 41岁)明显低于未复发的患者(n = 23;45±11,28 - 60岁;p < 0.001)。无患者出现临床内分泌功能障碍。仅4例患者接受过甲状腺素治疗,他们在甲状腺功能正常的FT4和T3水平且目前无甲状腺肿复发的情况下均抑制了TSH。22例患者未进行甲状腺激素预防,其中仅4例(18%)在长期随访中出现无地方性碘缺乏的复发。对于在非碘缺乏地区接受甲状腺切除术后经过仔细监测的低风险患者,通常不需要进行甲状腺激素预防。对于有复发风险的患者(二次甲状腺切除术、家族史、TSH升高、甲状腺生长的临床或超声证据),应考虑进行甲状腺素治疗并定期随访。